Clinical Trial Update: Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) [Phase 3]

View source ↗

Summary

This Phase 3 study evaluates switching HIV-1 patients from Bictegravir/Emtricitabine/Tenofovir Alafenamide to doravirine/islatravir; results have been posted af…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Islatravir (Islatravir)
• PIFELTRO (doravirine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infection | Phase 3 | Status: COMPLETED | Results posted: 2022-08-22